Q-omics provides the consensus-scored ERFL profile across patient tissues and cancer cell-line models. ERFL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ERFL is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ERFL RNA expression shows 16,071 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ERFL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERFL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERFL survival associations across molecular data types. ERFL RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERFL RNA expression–survival associations across cancer types. High ERFL expression shows unfavorable associations in KIRC, ACC, KIRP, MESO and READ, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ERFL RNA expression.
This table summarizes ERFL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ERFL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERFL shows higher tumor expression in HNSC, KIRC, KIRP, STAD, BRCA and KICH. The HNSC box plot shows higher ERFL RNA expression in tumor versus normal tissue (log2 FC = +0.461, t-test p < 0.001).
This table shows molecular features associated with ERFL in patient tissues and cancer cell lines. In patient samples, ERFL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
